{
  "outcomes_metadata": {
    "timestamp": "2025-09-29T13:02:12.541161",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 61,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "overall survival (time from randomisation to death from any cause)",
        "prolonged survival",
        "progression-free survival (PFS)",
        "progression-free survival (blinded independent central review)",
        "progression-free survival (RECIST v1.1)",
        "progression-free survival (independent review committee, RECIST 1.1)",
        "progression-free survival (sensitivity analysis: initiation of new anti-cancer therapy considered as event)",
        "progression-free survival (PFS; RECIST v1.1)",
        "event-free survival",
        "quality-adjusted life years (QALYs)"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (RECIST 1.1, blinded independent central review)",
        "objective response rate (independent review committee, RECIST 1.1)",
        "objective response rate (RECIST 1.1)",
        "overall response rate (ORR)",
        "response rates",
        "complete response (RECIST 1.1)",
        "partial response (RECIST 1.1)",
        "disease control rate",
        "disease control rate (complete, partial, or stable disease for at least 5 weeks)",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "time to response",
        "time to response (from treatment initiation to first complete or partial response)",
        "treatment duration",
        "duration of treatment"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to next treatment (TTNT)",
        "time to next treatment",
        "dropout rate",
        "morbidity and mortality associated with clinical events",
        "mortality-related toxicity"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (AEs)",
        "adverse events (general)",
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "adverse events (general; CTCAE v5.0)",
        "adverse events (Grade 3 or higher)",
        "grade 3 or higher adverse events",
        "serious adverse events (SAEs)",
        "serious adverse events",
        "serious adverse events (Grade 3-4)",
        "severe adverse events",
        "fatal adverse events",
        "treatment-related adverse events",
        "discontinuation due to adverse events",
        "treatment discontinuation due to adverse events",
        "interstitial lung disease (severe AE)",
        "liver disorders (severe AEs)",
        "stomatitis (AE)",
        "peripheral oedema (AE)",
        "peripheral neuropathy (AE)",
        "alopecia (AE)",
        "blood and lymphatic system disorders (AE)",
        "fatigue (AE)",
        "fatigue",
        "fever (AE)",
        "fever",
        "infections and infestations (AE)",
        "diarrhoea",
        "alanine aminotransferase increase",
        "aspartate aminotransferase increase",
        "neutropenia",
        "febrile neutropenia",
        "serious side effects on the skin"
      ],
      "serious_events": [
        "serious adverse events (SAEs)",
        "serious adverse events",
        "serious adverse events (Grade 3-4)",
        "fatal adverse events",
        "serious side effects on the skin"
      ],
      "discontinuations": [
        "discontinuation due to adverse events",
        "treatment discontinuation due to adverse events",
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF",
        "FACT-G GP5",
        "item GP5 of the FACT-G",
        "PGI-C",
        "PGIC",
        "PGIS",
        "EQ-5D-5L",
        "EQ-5D visual analogue scale (EQ-5D VAS)",
        "visual analogue scale",
        "NSCLC-SAQ",
        "PRO-CTCAE"
      ],
      "functional_status": [
        "Karnofsky performance status",
        "ECOG performance status",
        "physical functioning"
      ],
      "symptom_measures": [
        "symptomatology (patient-reported outcomes)",
        "symptom control",
        "changes in cancer-specific symptoms",
        "changes in overall health status",
        "health status",
        "overall health status",
        "health-related quality of life",
        "health-related quality of life measured by time to death",
        "quality of life",
        "preservation of quality of life",
        "physical benefits",
        "psychological benefits"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (cost per QALY)"
      ],
      "utilities": [
        "utility decrement per cycle of treatment",
        "progression-free survival utility",
        "progression-free survival on-treatment utility differential",
        "health-state utility"
      ],
      "resource_utilization": [
        "disutility for intravenous administration"
      ]
    },
    "other": {
      "exploratory_endpoints": [],
      "biomarkers": []
    }
  }
}